Ideaya Biosciences在其IDE 892治疗Mtap-100实体瘤的I/II期试验中启动了第2部分单药治疗扩展，重点关注非小细胞肺癌和胰腺导管腺癌

2026-07-27 18:12

IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative binding vs SAM-PRMT5 cooperative binding, and CYP3A4 IC50 greater than 45 micromolar with no time-dependent inhibition of the 7 major cytochrome P450s
IDE892 Phase 1/2 escalation has cleared multiple dose cohorts and projected efficacious target exposures have been achieved to initiate the Part 2 monotherapy expansion. The IDE892 escalation is ongoing in parallel and the MTD has not yet been reached
IDE892 and IDE397 combination escalation are ongoing in MTAP NSCLC and PDAC, and IDE892 and pan-RAS combination FPI in MTAP PDAC is targeted for H2 2026
MTAP-deletion is estimated to occur in up to 40% of PDAC and ~15% of NSCLC
IDEAYA is targeting a MTAP/CDKN2A, KRAS, and Pancreatic Cancer R&D Day in Q4 2026. Topics will include rational combination strategies to target the underlying tumor heterogeneity and adaptive plasticity in PDAC and other solid tumor indications